Last update: Aug. 6, 2017
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Usually used in combination with Ledispavir in the treatment of hepatitis C.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (moderately elevated molecular weight, good percentage of protein binding and very short half-life) impedes its passage to breast milk in significant amounts, so although there is disagreement (Thompson 2016), some authors consider that treatment with sofosbuvir, alone or in combination with ledipasvir is not contraindicated during breastfeeding (Spera 2016).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM